Compare MMU & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMU | CTNM |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 489.4M |
| IPO Year | N/A | 2024 |
| Metric | MMU | CTNM |
|---|---|---|
| Price | $10.30 | $12.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 124.6K | ★ 175.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.79 | $3.57 |
| 52 Week High | $10.71 | $16.33 |
| Indicator | MMU | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 47.44 |
| Support Level | $10.24 | $11.62 |
| Resistance Level | $10.29 | $13.26 |
| Average True Range (ATR) | 0.08 | 0.80 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 69.73 | 53.28 |
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.